Back to top

Corbus Pharmaceuticals (CRBP) Stock Moves -1.23%: What You Should Know

Read MoreHide Full Article

Corbus Pharmaceuticals (CRBP - Free Report) closed the most recent trading day at $7.23, moving -1.23% from the previous trading session. This move lagged the S&P 500's daily of 0%. Meanwhile, the Dow lost 0.3%, and the Nasdaq, a tech-heavy index, added 0.25%.

Heading into today, shares of the drug developer had gained 20.2% over the past month, outpacing the Medical sector's loss of 0.21% and the S&P 500's gain of 2.36% in that time.

Wall Street will be looking for positivity from CRBP as it approaches its next earnings report date. On that day, CRBP is projected to report earnings of $0 per share, which would represent year-over-year growth of 100%. Meanwhile, our latest consensus estimate is calling for revenue of $18.96 million, up 1895.79% from the prior-year quarter.

For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.85 per share and revenue of $22.18 million, which would represent changes of +13.27% and +359.89%, respectively, from the prior year.

Any recent changes to analyst estimates for CRBP should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 6.12% higher. CRBP currently has a Zacks Rank of #3 (Hold).

The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 72, which puts it in the top 29% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Corbus Pharmaceuticals Holdings, Inc. (CRBP) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in